Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621317 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
A Phase 2 study of Immune System Diseases and Peanut Allergy, sponsored by Aravax Pty.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 14
- Study locations
NCT05621317 is a Phase 2 study of Immune System Diseases and Peanut Allergy that is active but no longer recruiting, run by Aravax Pty. The registered enrollment target is 90 participants, below the 148-participant average among 18 other Immune System Diseases trials with a reported enrollment target (39% lower). The trial reports 14 study locations across 12 states.
The verdict
NCT05621317, a Phase 2 study of Immune System Diseases and Peanut Allergy, is active but no longer recruiting, sponsored by Aravax Pty.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 14
- Study locations
Study Summary
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PVX-108
Study Locations (14)
Maryland
- Johns Hopkins Hospital - Baltimore
- IAA Clinical Research - Chevy Chase
New South Wales
- Sydney Children's Hospital - Randwick
- The Children's Hospital at Westmead - Westmead
Arkansas
- Arkansas Children's Research Institute - Little Rock
California
- Peninsula Research Associates - Rolling Hills Estates
Georgia
- Children's Healthcare of Atlanta - Atlanta
Indiana
- Riley Children's Hospital at IU - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-02-09 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05621317
The ClinicalTrials.gov registry entry for NCT05621317 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148-participant average among 18 other Immune System Diseases trials with a reported enrollment target (39% lower). The listed sponsor is Aravax Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05621317 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Maryland, New South Wales, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05621317 about?
NCT05621317 is a clinical study titled "A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy". The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
What is the current status of trial NCT05621317?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2023-02-09. Estimated completion is 2027-06.
What conditions does trial NCT05621317 study?
This clinical trial studies the following conditions: Immune System Diseases, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis.
What interventions are being tested in trial NCT05621317?
The interventions under investigation include: Placebo (BIOLOGICAL), PVX-108 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05621317?
This trial is sponsored by Aravax Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05621317 being conducted?
This trial has 14 study locations across Arkansas, California, Georgia, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
RECRUITING · Phase 2
-
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RECRUITING · Phase 2
-
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
ACTIVE NOT RECRUITING · Phase 2
-
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.